Last Update 03 Feb 26

Fair value Increased 2.94%

ILMN: Future Returns Will Depend On China Access And 2026 Execution

Narrative Update: Illumina Analyst Target Shift

Our Analyst Price Target for Illumina moves modestly higher by about $4 per share as analysts cite updated views on revenue growth, profit margins, and future P/E multiples following a series of recent price target increases across the Street.

Analyst Commentary

Bullish and cautious voices are both weighing in on Illumina, and most of the recent activity centers on refreshed views for 2026, broader life science tools demand, and where valuation might settle after recent share moves.

Bullish Takeaways

Bullish analysts are lifting price targets by $20 to $26 per share in several cases, signaling that their models support higher potential equity value based on updated assumptions for revenue, margins, and P/E multiples.
Some see the life science tools group, including Illumina, as having room into 2026 after what they describe as companies already soft guiding that period, which they interpret as leaving potential room for upside versus those conservative assumptions.
There is emphasis on recovering end markets and a setup for what one analyst calls a 2026 tools play, which they connect to healthier procedure and capital expenditure trends and early signs of recovery in China, all feeding into their Illumina outlook.
Following recent quarterly results, at least one bullish analyst has raised a target into the high $100s per share while keeping a positive stance on the stock, pointing to execution and growth expectations as enough to support that target.

Bearish Takeaways

Not all analysts are aggressively positive, with at least one maintaining a Hold rating even after raising the target to $140 per share, which signals some hesitation about upside relative to the current share price.
Some cautious analysts highlight that share rallies heading into Q4 mean the bar for results is now higher, which could limit valuation expansion if Illumina’s reported numbers or guidance do not line up with raised expectations.
There is explicit concern around broader sector factors, such as potential changes to the Affordable Care Act and Medicare, which bearish analysts say have bears watching and could weigh on growth assumptions or investor sentiment.
Cautious views also point out that even with improving end market signals, execution against 2026 targets will be key, so any delays in capital spending or slower than expected momentum in China could challenge the more optimistic valuations now being used.

What’s in the News

Illumina is expected to appoint Eric Green, a former NIH director, as chief medical officer, signaling a focus on clinical leadership and medical oversight at the company (Endpoints News).
Reimbursement has been granted by the Centers for Medicare and Medicaid Services for Illumina's FDA approved TruSight Oncology Comprehensive test, with a set rate of US$2,989.55 under PLA code 0543U effective January 1, 2026. This creates a defined payment framework for Medicare patients using this comprehensive genomic profiling assay.
Illumina announced an agreement with Devyser that allows Devyser customers to access Illumina sequencing instruments through an ongoing reagent commitment model, aiming to lower upfront capital spending and support labs that want to expand genetic testing capability.
The company introduced the Illumina Billion Cell Atlas as part of a larger 5 billion cell program. It is working with AstraZeneca, Merck, and Eli Lilly to generate large scale CRISPR based single cell data for use in AI driven drug target research.
Chinese authorities plan to lift the export ban on Illumina on November 10 while keeping the company on the Unreliable Entities List. Instrument purchases in China still require government approval, which adds a layer of oversight to activity in that market.

Valuation Changes

Fair Value: Our fair value estimate has risen slightly from US$132.06 to US$135.94 per share.
Discount Rate: The discount rate has edged lower from 8.02% to 7.99%.
Revenue Growth: The revenue growth assumption has moved slightly higher from 4.44% to 4.50%.
Net Profit Margin: The net profit margin assumption has increased from 17.72% to 19.66%.
Future P/E: The assumed future P/E multiple has been trimmed from 26.35x to 24.38x.

Expansion in clinical genomics and next-generation sequencing adoption is driving strong, recurring revenue growth and future earnings visibility.
Ongoing innovation, multiomics expansion, and operational efficiency are enhancing gross margins and creating new growth opportunities.
Persistent research budget constraints, regulatory risks in China, rising competition, commoditization, and clinical dependency threaten Illumina's revenue growth, margins, and market position.

Catalysts

About Illumina

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.What are the underlying business or industry changes driving this perspective?

Strong and resilient growth in clinical applications-especially oncology, genetic disease testing, and reproductive health-continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility.
Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.
Ongoing innovation-evidenced by successful launches like MiSeq i100 Plus and increasing uptake of NovaSeq X-lowers barriers for new customer segments, enhances platform performance, and supports higher gross margins as transitions accelerate, particularly in the clinical segment.
Strategic expansion into multiomics, notably the planned acquisition of SomaLogic and integration of proteomics capabilities, creates incremental growth opportunities by increasing the breadth of Illumina's data and platform offerings, contributing to future revenue and operating margin expansion.
Operational efficiencies, disciplined cost controls, and targeted share repurchases have already resulted in notable operating margin and EPS improvements, and further scaling-along with tax headwinds turning into tailwinds-sets the stage for continued net margin and earnings growth over the next several years.

Illumina Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Illumina's revenue will grow by 3.6% annually over the next 3 years.
Analysts assume that profit margins will shrink from 29.3% today to 18.4% in 3 years time.
Analysts expect earnings to reach $873.5 million (and earnings per share of $5.66) by about September 2028, down from $1.3 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.0 billion in earnings, and the most bearish expecting $715.5 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 22.2x on those 2028 earnings, up from 12.0x today. This future PE is lower than the current PE for the US Life Sciences industry at 29.3x.
Analysts expect the number of shares outstanding to decline by 3.09% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.53%, as per the Simply Wall St company report.

Illumina Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Heightened U.S. research funding uncertainty and ongoing NIH budget constraints are leading to persistent softness in the research end-market, significantly limiting instrument purchases and creating a negative long-term headwind for revenue growth and earnings diversification.
Increased export restrictions and regulatory uncertainties in China are causing a sustained decline in Chinese instrument and consumables revenue; management notes the situation is currently unsustainable, indicating elevated risk to international revenue streams and future top-line growth.
Intensifying competition, particularly from upcoming platforms like Roche's with faster turnaround times, poses the risk of price pressure, potential market share loss, and margin compression, especially as the market for high
and mid-throughput sequencing matures.
There is ongoing commoditization of next-generation sequencing (NGS) technology as well as a shift towards decentralized, benchtop sequencers like the MiSeq i100, which could lower barriers for competitors, shift purchasing patterns, and erode gross margins and operating leverage over time.
The company's dependence on continued strong growth in clinical applications carries risk; if clinical adoption or reimbursement slows, demand for sequencing platforms and consumables could weaken, leading to lower revenue growth and potential negative impact on earnings and margins, especially as clinical now makes up over 60% of consumables revenue.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $111.952 for Illumina based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $185.0, and the most bearish reporting a price target of just $75.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $4.8 billion, earnings will come to $873.5 million, and it would be trading on a PE ratio of 22.2x, assuming you use a discount rate of 7.5%.
Given the current share price of $98.22, the analyst price target of $111.95 is 12.3% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Illumina?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ILMN: Operational Progress Will Offset Ongoing China Exposure And Sector Uncertainties